Individuals for whom we have a valid mailing address will receive a direct notification letter if their data may have been impacted. If you have questions or think you may be impacted, please call ...

In recent years, the application of picosecond laser (PSL) treatment for skin discoloration caused by nevus of Ota has been ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor ...

“The data presented at ASCO strengthen our conviction that ziftomenib has potential to become a meaningful treatment option for patients with relapsed or refractory AML with NPM1 mutations — patients ...

Relevant, timely content extends conversations: Content-driven HCP engagements double treatment starts while extending conversations. Time between meetings is shortened by up to 25% increasing the ...

Early clinical data showed that C-CAR168 was well tolerated. Four LN patients and one SPMS patient experienced low-grade 1-2 CRS with median time to onset of 2 days post C-CAR168 treatment.

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis By {fullname} 21-05-2025, 07:50 89 ...